Alvotech further strengthens liquidity by securing term loan facility of $75 million
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) amended its credit agreement to add a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. The loan bears 12.50% interest, payable monthly in cash.
Alongside a recent $165 million equity raise and an existing $100 million term loan, Alvotech now has access to $240 million in new capital to fund its biosimilar R&D pipeline, FDA-related activities, product launches and global commercial expansion.
Positive
- Access to up to $75 million additional term loan funding
- Total new capital access of $240 million including equity and undrawn facility
- $165 million equity capital raise completed June 18, 2026
- Loan maturity extended to December 31, 2027 for added liquidity runway
- Capital earmarked to support biosimilar R&D, FDA filings and global launches
Negative
- New term loan bears relatively high 12.50% cash interest rate
- Incremental debt of up to $75 million increases leverage and interest burden
- Term loan facility matures on December 31, 2027, creating future refinancing need
News Market Reaction – ALVO
In the Jul 1 session, ALVO declined 2.98%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | Insider-related buying | Positive | +1.4% | Manager‑associated entity acquired over 10 million shares at a set price. |
| Jun 18 | Equity offering closed | Negative | +0.1% | Closed $165M public offering and private placement issuing new shares. |
| Jun 18 | Equity raise announced | Negative | +0.1% | Announced proposed $125M public offering and concurrent private placement. |
| Jun 15 | Offering priced | Negative | -8.7% | Priced $152M offering and private placement to fund development and debt. |
| Jun 15 | Offering launched | Negative | -8.7% | Launched proposed $125M public offering and concurrent private placement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent capital-raising announcements often trigger sharp but mixed reactions, with some offerings selling off and others seeing little or positive price impact.
Key Terms
term loan facility financial
equity capital raise financial
biologics license applications regulatory
biosimilar medical
interest rate financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
$75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management- Follows recent
$165m equity raise strengthening cash position - Including equity financing and undrawn loan facility, Alvotech has secured access to
$240 million in new capital - Funds will support execution across Alvotech’s R&D pipeline and global product launches
REYKJAVIK, ICELAND (July 1, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has amended its existing credit agreement with funds managed by GoldenTree Asset Management LP and other existing lenders of Alvotech to provide a term loan facility of up to
The financing further strengthens Alvotech's financial position following the
“This financing provides additional flexibility as we continue to execute on our strategic priorities and support the next phase of growth for Alvotech," said Robert Wessman, founder and chairman of Alvotech. “The strong support we received from both existing shareholders and more than 40 new specialist healthcare investors in our recent equity offering, together with this additional financing, reflects growing confidence in Alvotech, our strategy and the opportunities ahead.
“Over the past several months we have achieved important milestones across our business, including the resubmission of key Biologics License Applications to the FDA, continued advancement of our pipeline including FDA acceptance of our BLA for a biosimilar to Entyvio®, and the expansion of our global commercial footprint. These achievements reinforce our belief that we are building one of the world’s leading biosimilars companies.
“With approximately 30 biosimilar products in development and a growing portfolio of commercial opportunities, we see a significant opportunity to increase patient access to affordable biologic medicines around the world.
“Capital is the fuel that enables us to execute on that vision, and this financing further strengthens our ability to invest in growth and create long-term value for patients, partners and shareholders.”
The financing builds on Alvotech's existing relationship with GoldenTree, which has been a long-term financing partner to the company. It expands the company’s existing credit agreement by providing an additional
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad
Benedikt Stefansson
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding the adequacy and comprehensiveness of the data package to support the demonstration of biosimilarity and interchangeability for AVT16, business prospects and opportunities including pipeline product development, including AVT16 and AVT80, future plans and intentions, regulatory review and interactions, the potential approval, interchangeable designation and commercial launch of its product candidates, and Alvotech’s mission to expand patient access to biologic medicines. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.
